The DOI matches its Crossref record; 47 of the 51 references it cites were found in a registry or an index.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Open accessAbstract
Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 ( IDH1 ) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic and molecular markers of malignant tumors have been integrated into clinical practice 5,6 , with the US Food and Drug Administration (FDA) providing approval for several companion diagnostic devices and nucleic acid-based tests 7,8 .”
From Multimodal biomedical AI (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PI3K signaling is hyperactivated in nearly 90% of GBMs, commonly as a consequence of EGFR amplification and activating mutation (EGFRvIII), and loss of the PTEN tumor suppressor protein, a negative regulator of PI3K signaling (6–8).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“The IDH genes (IDH1 and IDH2) encode isocitrate dehydrogenases, and mutations in these genes are among the most frequent found in diffuse gliomas118,119.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [118]
In the citing paper
“Moreover, in the context of DNA damage, MDM2 localizes to the nucleus and modulates DNA repair in a p53-independent manner by binding to and inactivating Nbs1 in the MRE11/Rad50/NBS1 complex.1,8,27”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [27]
In the citing paper
“Cancer genome sequencing efforts yielded an unexpected discovery in 2008 with the identification of somatic mutations in a metabolic enzyme, the TCA cycle enzyme IDH1, in glioblastoma multiforme (GBM) (77).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [77]
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the presence of IDH1/2 mutations in gliomas is associated with both lower histological grade and a slower rate of disease progression”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Parsons et al., 2008
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
SIFT: predicting amino acid changes that affect protein function
Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,601
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationSerial Analysis of Gene Expression
Velculescu, V. E., Zhang, L., Vogelstein, B., & Kinzler, K. W. (1995) · Science · doi:10.1126/science.270.5235.484 · Cited by 3,713
Self-citationHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Self-citation
Flagged first, then by citations
4 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- H. Scherer, Am. J. Cancer40, 159 (1940).
- R. J. Learyet al. Proc. Natl. Acad. Sci. U.S.A. in press.
- K. Uekiet al., Cancer Res.56, 150 (1996).
- L. Frederick, X. Y. Wang, G. Eley, C. D. James, Cancer Res.60, 1383 (2000).
- G. Thielet al., Anticancer Res.15, 2495 (1995).
- S. Ekins, Y. Nikolsky, A. Bugrim, E. Kirillov, T. Nikolskaya, Methods Mol. Biol.356, 319 (2007).
- Contact information for the authors who directed the major components of this project is as follows: H. Yan G. J. Riggins (clinical and sample coordination) yan00002@mc.duke.edu griggin1@jhmi.edu; D. D. Bigner (pathological and clinical review) bigne001@mc.duke. edu; R. Karchin (bioinformatic analysis) karchin@jhu.edu; N. Papadopoulos (gene expression analysis) npapado1@jhmi.edu; G. Parmigiani (statistical analysis) gp@jhu.edu; B. Vogelstein V. E. Velculescu K. W. Kinzler (sequencing and copy number analysis) bertvog@gmail.com velculescu@jhmi.edu kinzlke@jhmi.edu. We thank N. Silliman J. Ptak L. Dobbyn and M. Whalen for assistance with PCR amplification; D. Lister L. J. Ehinger D. L. Satterfield J. D. Funkhouser and P. Killela for assistance with DNA purification; T. Sjöblom for assistance with database management; the Agencourt sequencing team for assistance with automated sequencing; and C.-S. Liu and the SoftGenetics team for their assistance with mutation detection analyses. This project was carried out under the auspices of the Ludwig Brain Tumor Initiative and was supported by the Virginia and D. K. Ludwig Fund for Cancer Research NIH grants CA121113 NS052507 CA43460 CA57345 CA62924 CA09547 5P50-NS-20023 CA108786 and CA11898 the Pew Charitable Trusts the Pediatric Brain Tumor Foundation Institute the Hirschhorn Foundation Alex's Lemonade Stand Foundation the American Brain Tumor Association the American Society of Clinical Oncology the Brain Tumor Research Fund and Beckman Coulter Corporation. Under separate licensing agreements between the Johns Hopkins University and Genzyme Beckman Coulter and Exact Sciences Corporations B.V. V.E.V. and K.W.K. are entitled to a share of royalties received by the university on sales of products related to research described in this paper. These authors and the university own Genzyme and Exact Sciences stock which is subject to certain restrictions under university policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.
Cited by
Sorted by citations
Items 701–800 of 1,034
Glutamate and α-ketoglutarate: key players in glioma metabolism
Maus, A., & Peters, G. J. (2016) · Amino Acids · doi:10.1007/s00726-016-2342-9 · Cited by 162
Metabolic Adaptations in Cancer Stem Cells
Yadav, U. P., Singh, T., Kumar, P., Sharma, P., Kaur, H., Sharma, S., Singh, S., Kumar, S., & Mehta, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01010 · Cited by 158
Structure-based systems biology for analyzing off-target binding
Xie, L., Xie, L., & Bourne, P. E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.004 · Cited by 155
Tumor suppressor functions of FBW7 in cancer development and progression
Wang, Z. P., Inuzuka, H., Zhong, J., Wan, L., Fukushima, H., Sarkar, F. H., & Wei, W. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.017 · Cited by 154
Targeted Therapy for BRAFV600E Malignant Astrocytoma
Nicolaides, T. P., Li, H., Solomon, D. A., Hariono, S., Hashizume, R., Barkovich, K. J., Baker, S. J., Paugh, B. S., Jones, C., Forshew, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1456 · Cited by 154
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 154
The Roles of 2-Hydroxyglutarate
Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 160
Cheng, H.-W., Liang, Y.-H., Kuo, Y.-L., Chuu, C.-P., Lin, C.-Y., Lee, M. H., Wu, A. T. H., Yeh, C.-T., Chen, E. I.-T., Whang-Peng, J., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.77 · Cited by 152
Is Anticancer Drug Development Heading in the Right Direction?
Hambley, T. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3786 · Cited by 153
Song, Y., Wu, F., & Wu, J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0279-9 · Cited by 154
Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 162
Sun, M., Hillmann, P., Hofmann, B. T., Hart, J. R., & Vogt, P. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009652107 · Cited by 155
Makishima, H., Jankowska, A. M., McDevitt, M. A., O’Keefe, C. L., Dujardin, S., Cazzolli, H., Przychodzen, B. P., Prince, C. J., Nicoll, J. M., Harish, S., et al. (2011) · Blood · doi:10.1182/blood-2010-06-292433 · Cited by 155
Bardella, C., Al‐Dalahmah, O., Krell, D., Brazauskas, P., Al‐Qahtani, K., Tomková, M., Adam, J., Serres, S., Lockstone, H. E., Freeman-Mills, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.017 · Cited by 157
Talasila, K. M., Soentgerath, A., Euskirchen, P., Røsland, G. V., Wang, J., Huszthy, P. C., Prestegarden, L., Skaftnesmo, K. O., Sakariassen, P. Ø., Eskilsson, E., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1101-1 · Cited by 153
Ranganathan, P., Clark, P. A., Kuo, J. S., Salamat, M. S., & Kalejta, R. F. (2011) · Journal of Virology · doi:10.1128/jvi.06097-11 · Cited by 149
Key contribution of CPEB4-mediated translational control to cancer progression
Zapater, E. O., Pineda, D., Martínez‐Bosch, N., Fernández‐Miranda, G., Iglesias, M., Alameda, F., Moreno, M., Eliscovich, C., Eyras, E., Real, F. X., et al. (2011) · Nature Medicine · doi:10.1038/nm.2540 · Cited by 149
Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148
Grzmil, M., Morin, P., Lino, M. M., Merlo, A., Frank, S., Wang, Y., Moncayo, G. E., & Hemmings, B. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3112 · Cited by 150
ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies
Rinaldi, M., Caffo, M., Minutoli, L., Marini, H. R., Abbritti, R. V., Squadrito, F., Trichilo, V., Valenti, A., Barresi, V., Altavilla, D., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060984 · Cited by 151
The molecular feature of macrophages in tumor immune microenvironment of glioma patients
Zhang, H., Luo, Y., Wu, W., Zhang, L., Wang, Z., Dai, Z., Feng, S., Cao, H., Cheng, Q., & Liu, Z. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.019 · Cited by 150
The Salmonella Mutagenicity Assay: The Stethoscope of Genetic Toxicology for the 21st Century
Claxton, L. D., Umbuzeiro, G. D. A., & DeMarini, D. M. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.1002336 · Cited by 148
Mo, W., Chen, J., Patel, A. J., Zhang, L., Chau, V., Li, Y., Cho, W., Lim, K., Xu, J., Lazar, A. J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.053 · Cited by 150
Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase
Gantke, T., Sriskantharajah, S., & Ley, S. C. (2010) · Cell Research · doi:10.1038/cr.2010.173 · Cited by 154
Hodgson, J., Yeh, R.-F., Ray, A., Wang, N. J., Smirnov, I. V., Yu, M., Hariono, S., Silber, J., Feiler, H. S., Gray, J. W., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-113 · Cited by 149
Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma
Burnichon, N., Buffet, A., Parfait, B., Letouzé, É., Laurendeau, I., Loriot, C., Pasmant, É., Abermil, N., Valeyrie‐Allanore, L., Bertherat, J. Y., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds374 · Cited by 159
The Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 149
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
Huang, J., Yu, J., Tu, L., Huang, N., Li, H., & Luo, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00506 · Cited by 147
Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments
Rajaratnam, V., Islam, M. M., Yang, M., Slaby, R., Ramirez, H. M., & Mirza, S. P. (2020) · Cancers · doi:10.3390/cancers12040937 · Cited by 152
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Yuan, K., Wang, X., Dong, H., Min, W., Hao, H., & Yang, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.001 · Cited by 148
MODBASE, a database of annotated comparative protein structure models and associated resources
Pieper, U., Eswar, N., Webb, B., Eramian, D., Kelly, L., Barkan, D. T., Carter, H., Mankoo, P. K., Karchin, R., Martı́-Renom, M. A., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn791 · Cited by 147
Self-citationMetabolic management of brain cancer
Seyfried, T. N., Kiebish, M. A., Marsh, J., Shelton, L. M., Huysentruyt, L. C., & Mukherjee, P. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.08.009 · Cited by 148
Takai, H., Masuda, K., Sato, T., Sakaguchi, Y., Suzuki, T., Suzuki, T., Koyama‐Nasu, R., Nasu‐Nishimura, Y., Katou, Y., Ogawa, H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.071 · Cited by 151
Whole-Exome Sequencing Studies of Nonhereditary (Sporadic) Parathyroid Adenomas
Newey, P. J., Nesbit, M. A., Rimmer, A. J., Attar, M., Head, R. T., Christie, P. T., Gorvin, C. M., Stechman, M., Gregory, L., Mihai, R., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2303 · Cited by 146
Emerging Insights into Barriers to Effective Brain Tumor Therapeutics
Woodworth, G. F., Dunn, G. P., Nance, E. A., Hanes, J. S., & Brem, H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00126 · Cited by 153
Inborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 147
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 152
Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer
Yi, J. M., Dhir, M., Neste, L. V., Downing, S. R., Jeschke, J., Glöckner, S. C., Calmon, M. F., Hooker, C. M., Funes, J. M., Boshoff, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2509 · Cited by 145
Oncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · FEBS Journal · doi:10.1111/febs.13295 · Cited by 148
Analysis of next-generation genomic data in cancer: accomplishments and challenges
Ding, L., Wendl, M. C., Koboldt, D. C., & Mardis, E. R. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq391 · Cited by 148
Lei, L., Sonabend, A. M., Guarnieri, P., Soderquist, C. R., Ludwig, T. E., Rosenfeld, S. A., Bruce, J. N., & Canoll, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020041 · Cited by 149
Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.298 · Cited by 147
Regulation of Brain Tumor Dispersal by NKCC1 Through a Novel Role in Focal Adhesion Regulation
Garzón-Muvdi, T., Schiapparelli, P. V., Rhys, C. M. J. A., Guerrero‐Cazares, H., Smith, C. L., Kim, D., Kone, L. B., Farber, H., Lee, D. Y., An, S. S., et al. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001320 · Cited by 144
Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC
Kitzing, T. M., Wang, Y., Pertz, O. C., Copeland, J. W. R., & Grosse, R. (2010) · Oncogene · doi:10.1038/onc.2009.515 · Cited by 144
Gorovets, D. J., Kannan, K. S., Shen, R., Kastenhuber, E. R., Islamdoust, N., Campos, C., Pentsova, E. I., Heguy, A., Jhanwar, S. C., Mellinghoff, I. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2977 · Cited by 145
Fack, F., Tardito, S., Hochart, G., Oudin, A., Zheng, L., Fritah, S., Golebiewska, A., Nazarov, P. V., Bernard, A., Hau, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707729 · Cited by 148
Luan, W., Wang, Y., Chen, X., Shi, Y., Wang, J., Zhang, J., Qian, J., Li, R., Tao, T., Wei, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3514 · Cited by 146
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Wang, J.-H., Chen, W., Li, J., Wu, S., Chen, T., Zhu, Y., Zhang, W., Li, Y., Qiu, Y.-P., Zhao, A.-H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315558110 · Cited by 146
IκB kinase regulation of the TPL‐2/ERK MAPK pathway
Gantke, T., Sriskantharajah, S., Sadowski, M. I., & Ley, S. C. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01104.x · Cited by 147
Benítez, J. A., Ma, J., D’Antonio, M., Boyer, A. D., Camargo, M. F., Zanca, C., Kelly, S., Khodadadi‐Jamayran, A., Jameson, N. M., Andersen, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15223 · Cited by 147
Wick, W., Dettmer, S., Berberich, A., Keßler, T., Karapanagiotou‐Schenkel, I., Wick, A., Winkler, F., Pfaff, E., Brors, B., Debus, J., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy161 · Cited by 145
Kadiyala, P., Carney, S. V., Gauss, J. C., Garcia-Fabiani, M. B., Haase, S., Alghamri, M. S., Núñez, F. J., Liu, Y., Yu, M., Taher, A. W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139542 · Cited by 143
Marie, S. K. N., & Oba‐Shinjo, S. M. (2011) · Clinics · doi:10.1590/s1807-59322011001300005 · Cited by 148
Self-citationUncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma
Sun, J., Gong, X. Q., Purow, B. W., & Zhao, Z. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002488 · Cited by 144
Genetic and epigenetic heterogeneity in cancer: A genome‐centric perspective
Heng, H. H., Bremer, S. W., Stevens, J. B., Ye, K. J., Liu, G., & Ye, C. J. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21799 · Cited by 142
Clinical development of metabolic inhibitors for oncology
Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R., & Slusher, B. S. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148550 · Cited by 142
Identification of Driver and Passenger DNA Methylation in Cancer by Epigenomic Analysis
Kalari, S. K., & Pfeifer, G. P. (2010) · Advances in genetics · doi:10.1016/b978-0-12-380866-0.60010-1 · Cited by 143
Reifenberger, G., Weber, R. G., Riehmer, V., Kaulich, K., Willscher, E., Loeffler‐Wirth, H., Gietzelt, J., Hentschel, B., Westphal, M., Simon, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28836 · Cited by 141
Update on molecular findings, management and outcome in low-grade gliomas
Bourne, T. D., & Schiff, D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.159 · Cited by 146
Brain tumor stem cells: The cancer stem cell hypothesis writ large
Dirks, P. B. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.08.001 · Cited by 144
Pathway inhibition: emerging molecular targets for treating glioblastoma
Wick, W., Weller, M., Weiler, M., Batchelor, T. T., Yung, A. W. K., & Platten, M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor039 · Cited by 145
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
Bralten, L. B. C., Kloosterhof, N. K., Balvers, R. K., Sacchetti, A., Lapre, L., Lamfers, M. L. M., Leenstra, S., de Jonge, H. R., Kros, J. M., Jansen, E. E. W., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22390 · Cited by 148
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
Heffron, T. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00618 · Cited by 144
DNA methylation aberrancies as a guide for surveillance and treatment of human cancers
Liang, G., & Weisenberger, D. J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1311434 · Cited by 145
Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 143
Andronesi, O. C., Arrillaga‐Romany, I., Ly, I., Bogner, W., Ratai, E., Reitz, K., Iafrate, A. J., Dietrich, J., Gerstner, E. R., Chi, A. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03905-6 · Cited by 141
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 147
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
Sonoda, Y., Kumabe, T., Nakamura, T., Saito, R., Kanamori, M., Yamashita, Y., Suzuki, H., & Tominaga, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01270.x · Cited by 140
Anton, K., Baehring, J. M., & Mayer, T. M. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.04.006 · Cited by 145
Protective roles of matrix metalloproteinases: From mouse models to human cancer
López-Otı́n, C., Palavalli, L. H., & Samuels, Y. (2009) · Cell Cycle · doi:10.4161/cc.8.22.9956 · Cited by 140
Que, T., Song, Y., Liu, Z., Zheng, S., Long, H., Li, Z., Liu, Y., Wang, G., Liu, Y., Zhou, J., et al. (2015) · Oncogene · doi:10.1038/onc.2014.419 · Cited by 139
Self-citationNeurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications
Gottfried, O. N., Viskochil, D. H., & Couldwell, W. T. (2009) · Neurosurgical FOCUS · doi:10.3171/2009.11.focus09221 · Cited by 139
Sadiković, B., Yoshimoto, M., Chilton‐MacNeill, S., Thorner, P. S., Squire, J. A., & Zieleńska, M. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp117 · Cited by 141
Deng, G., Shen, J., Yin, M., McManus, J., Mathieu, M., Gee, P., He, T., Shi, C., Bedel, O., McLean, L. R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608497 · Cited by 138
Polívka, J., Polívka, J., Holubec, L., Kubíková, T., Přibáň, V., Hes, O., Pivovarčíková, K., & Třešková, I. (2017) · Anticancer Research · doi:10.21873/anticanres.11285 · Cited by 145
Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
Colardo, M., Segatto, M., & Bartolomeo, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094899 · Cited by 141
Obre, E., & Rossignol, R. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.12.008 · Cited by 137
Green, C. L., Evans, C. M., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2010) · Blood · doi:10.1182/blood-2010-02-270926 · Cited by 139
Childhood brain tumors: epidemiology, current management and future directions
Pollack, I. F., & Jakacki, R. I. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.110 · Cited by 137
Lou, M., Zhang, L., Ji, P., Feng, F., Liu, J.-H., Chen, Y., Li, B.-F., & Wang, L. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.08.055 · Cited by 138
Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification
Blümcke, I., Aronica, E., Becker, A. J., Capper, D., Coras, R., Honavar, M., Jacques, T. S., Kobow, K., Miyata, H., Mühlebner, A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.173 · Cited by 139
Meningiomas and neurofibromatosis
Goutagny, S., & Kalamarides, M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0339-x · Cited by 137
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
Bastien, J., McNeill, K. A., & Fine, H. A. (2014) · Cancer · doi:10.1002/cncr.28968 · Cited by 146
Early phase clinical trials to identify optimal dosing and safety
Cook, N., Hansen, A. R., Siu, L. L., & Razak, A. R. A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.025 · Cited by 136
Sadiković, B., Thorner, P. S., Chilton‐MacNeill, S., Martin, J. W., Cervigne, N. K., Squire, J. A., & Zieleńska, M. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-202 · Cited by 138
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
Chiang, S., Weigelt, B., Wen, H., Pareja, F. G., Raghavendra, A., Martelotto, L. G., Burke, K. A., Basili, T., Li, A., Geyer, F. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0298 · Cited by 137
Glioblastoma, hypoxia and autophagy: a survival-prone ‘ménage-à-trois’
Jawhari, S., Ratinaud, M., & Verdier, M. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.318 · Cited by 138
Gopal, U., Bohonowych, J. E. S., Tomé, C. M. L., Liu, A., Garrett-Mayer, E. S., Wang, B., & Isaacs, J. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017649 · Cited by 139
Fortelny, N., & Bock, C. (2020) · Genome Biology · doi:10.1186/s13059-020-02100-5 · Cited by 135
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Paolillo, M., Boselli, C., & Schinelli, S. (2018) · Brain Sciences · doi:10.3390/brainsci8010015 · Cited by 135
Yan, W., Zhang, W., You, G., Bao, Z., Wang, Y., Liu, Y., Kang, C., You, Y., Wang, L., & Jiang, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030339 · Cited by 135
The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
McLaughlin, S. K., Olsen, S. N., Dake, B. T., Raedt, T. D., Lim, E., Bronson, R. T., Beroukhim, R., Polyák, K., Brown, M. A., Kuperwasser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.004 · Cited by 137
Banasavadi‐Siddegowda, Y., Russell, L., Frair, E. C., Karkhanis, V. A., Relation, T., Yoo, J. Y., Zhang, J., Sif, S., Imitola, J., Baiocchi, R. A., et al. (2016) · Oncogene · doi:10.1038/onc.2016.199 · Cited by 137
Miller, A. D., Miller, C. R., & Rossmeisl, J. H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01151 · Cited by 136
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Shi, D. D., Savani, M. R., Levitt, M. M., Wang, A. C., Endress, J. E., Bird, C. E., Buehler, J., Stopka, S. A., Regan, M. S., Lin, Y., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.011 · Cited by 140
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1407-8 · Cited by 142
Sami, A., & Karsy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0800-5 · Cited by 137
CpG Island Hypermethylation in Human Astrocytomas
Wu, X., Rauch, T. A., Zhong, X., Bennett, W. P., Latif, F., Krex, D., & Pfeifer, G. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3631 · Cited by 134
Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer
Blackford, A. L., Parmigiani, G., Kensler, T. W., Wolfgang, C. L., Jones, S., Zhang, X., Parsons, D. W., Lin, J., Leary, R. J., Eshleman, J. R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0015 · Cited by 134
Self-citationGoyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 134
Metadata
- Authors
- Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., Olivi, A., McLendon, R., Rasheed, B. A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D. A., Tekleab, H., Diaz, L. A., Hartigan, J., Smith, D. R., Strausberg, R. L., Marie, S. K. N., Shinjo, S. M. O., Yan, H., Riggins, G. J., Bigner, D. D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., & Kinzler, K. W.
- Affiliations
- Howard Hughes Medical Institute (US)
- Ludwig Center for Cancer Genetics and Therapeutics, and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
- Corresponding author
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Angenendt, Philipp
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- ORCID
- Parsons, D. Williams
- Zhang, Xiaosong
- Lin, Jimmy Cheng-Ho
- Leary, Rebecca J.
- Carter, Hannah
- Gallia, Gary L.
- Olivi, Alessandro
- McLendon, Roger
- Keir, Stephen
- Diaz, Luis A.
- Marie, Suely Kazue Nagahashi
- Yan, Hai
- Riggins, Gregory J.
- Bigner, Darell D.
- Karchin, Rachel
- Parmigiani, Giovanni
- Vogelstein, Bert
- Velculescu, Victor E.
- Kinzler, Kenneth W.
- Venue
- Science
- Published
- 2008-09-26
- Volume
- 321
- Issue
- 5897
- Pages
- 1807-1812
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2820389
- OpenAlex
- W2040827479
- Cited by
- 5,857
- References
- 51
- Citations by year
- 2026: 131 · 2025: 160 · 2024: 189 · 2023: 260 · 2022: 256 · 2021: 370 · 2020: 344 · 2019: 313 · 2018: 329 · 2017: 347 · 2016: 353 · 2015: 373 · 2014: 410 · 2013: 428 · 2012: 457
- FWCI
- 172.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca121113-15, 5p50ns020023-30)
- National Cancer Institute (CA108786., CA 57345, R01-CA121113, CA-121113, CA43460, CA-11898, R37CA043460, CA09547, P50CA108786, R01CA140316, P50CA062924, R37CA057345, T32CA009547, CA 62924)
- National Institute of Neurological Disorders and Stroke (5P50NS20023, R01NS052507, NS052507)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- glioblastoma, IDH1 mutation, IDH1, somatic mutations, gene amplification, gene deletion, gene expression profiling, secondary glioblastoma, overall survival, targeted therapy
- MeSH terms
- Adult, Brain Neoplasms, Female, Gene Amplification, Glioblastoma, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Rate, Sequence Analysis, DNA, Gene Dosage, Mutation, Missense, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
